Skip to main content
FDA pushes for age diversity in cancer drug trials

The FDA is encouraging sponsors of clinical trials for cancer drugs to enroll more patients older than 65, beginning with early-stage studies, when it is safe and ethical to do so. In draft guidance, the FDA says older patients should be recruited in early-stage studies "to obtain information on safety, exposure, and response to better inform the study design and dose selection of later phase studies."

Full Story: